In the present review, we focus more specifically on mechanisms supporting the role of the SNS in the establishment of breast cancer cell metastases in the skeleton, and on how this knowledge supports the potential of βAR blockade as a new therapeutic strategy for a better management of patients with skeletal breast cancer metastases. This evidence concerns the gene ADRB2 and breast carcinoma.